All ICD10 Codes

DRG 018

Medical DRG

Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies

TypeMedical

What is MS-DRG 018?

MS-DRG 018 is a Medical Medicare Severity Diagnosis Related Group. For FY 2026 it carries a relative weight of 43.1828 with a geometric mean length of stay of 12.4 days and an arithmetic mean of 14.7 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.

Classification
Medical DRG
Diagnosis-driven grouping
MDC
Pre-MDC / Multi-MDC
Linked Codes
0 diagnosis
42 procedure

FY 2026 Payment Data

Official values from Table 5 of the FY 2026 IPPS Final Rule (CMS).

Relative Weight
43.1828
Payment multiplier vs. average case (1.0)
Geometric Mean LOS
12.4 days
Used for transfer payment calculations
Arithmetic Mean LOS
14.7 days
Average length of stay
Post-Acute Transfer
No
Not subject to the transfer policy

Linked ICD-10-PCS Procedure Mappings

  • XHR0XGA

    Replacement of Head and Neck Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR1XGA

    Replacement of Chest Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR2XGA

    Replacement of Abdomen Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR3XGA

    Replacement of Back Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR4XGA

    Replacement of Right Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR5XGA

    Replacement of Left Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR6XGA

    Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XHR7XGA

    Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

    BillableSection X
  • XW0331B

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW03368

    Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW03378

    Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW0338A

    Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033A7

    Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033BA

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033C7

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033FA

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW033FB

    Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW033G7

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033H7

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033J7

    Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033K7

    Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033L7

    Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033M7

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033N7

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW033RB

    Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW0431B

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW04368

    Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW04378

    Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

    BillableSection X
  • XW0438A

    Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043A7

    Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043BA

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043C7

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043FA

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

    BillableSection X
  • XW043FB

    Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X
  • XW043G7

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043H7

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043J7

    Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043K7

    Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043L7

    Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043M7

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043N7

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

    BillableSection X
  • XW043RB

    Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11

    BillableSection X